Neuroprotection in early stages of Alzheimer's disease is promoted by transthyretin angiogenic properties.
Tiago GiãoJoana SaavedraJosé Ricardo VieiraMarta Teixeira PintoGemma ArsequellIsabel CardosoPublished in: Alzheimer's research & therapy (2021)
Our in vivo results demonstrate the involvement of TTR in angiogenesis, particularly as a modulator of vascular alterations occurring in AD. Since TTR is decreased early in AD, its tetrameric stabilization can represent a therapeutic avenue for the early treatment of AD through the maintenance of the vascular structure.